Castle Biosciences to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum

FRIENDSWOOD, Texas--()--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO, will be presenting at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum on Thursday, November 19th, 2015 at 1:00 p.m. EST in New York.

The live audio webcast and subsequent replay may be accessed by visiting Please connect to the website at least 15 minutes prior to the live webcast to ensure adequate time for any necessary software download.

About Castle Biosciences

Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow-up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with uveal melanoma (DecisionDx-UM), cutaneous melanoma (DecisionDx-Melanoma) and esophageal cancer (DecisionDx-EC), among others. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at

DecisionDx-UM, DecisionDx-Melanoma and DecisionDx-EC are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.


Castle Biosciences, Inc.
James L Dunn, Jr., 866-788-9007
BMC Communications, LLC
Brad Miles, 646-513-3125

Recent Stories

RSS feed for Castle Biosciences, Inc.